We’re committed to creating better outcomes for patients and providers around the world. It’s a commitment that we take very seriously and one that requires a meaningful investment in the innovations that will reshape healthcare. This isn’t a new concept for BD. In fact, it’s what we’ve built our nearly 125-year legacy on. We identify the potential to reinvent healthcare, get a grasp on the specific problem at hand and invest to innovate—ultimately redefining what we consider to be our core products of today.

To deliver our robust innovation pipeline, we’ll continue to innovate in our core solutions—the 45 billion devices we already manufacture each year, which are often considered the backbone of healthcare: catheters, syringes, urinary catheters, acute care pumps and IV sets, hernia mesh and blood culture testing—just to name a few. At the same time, we’re focused on delivering breakthrough technologies aligned to three forces transforming healthcare: Smart Connected Care, the Transition to New Care Settings and Improved Chronic Disease Outcomes. In each of these categories, our expertise—matched by the breadth and depth of our core products—makes us uniquely positioned to develop solutions that will enhance care and create long-term value.

Here’s why.

Smart Connected Care

Smart Connected Care is a rapidly moving force, in which AI, informatics and robotics are transforming healthcare processes, tools and treatments in innovative ways. These sophisticated tools can help providers take a more comprehensive approach for disease management, better coordinate care plans and help patients to better manage and comply with their treatment plans.

We see a clear mandate in using these tools to help eliminate siloes in healthcare treatment—providing clinical benefits to both patients and providers. We’re leveraging our technical know-how to make new, smarter devices, increase automation and informatics in laboratories, and developing ever-more-connected medication management solutions.

Transition to New Care Settings

COVID-19 has rapidly accelerated the shift to new and alternate care settings, given the tremendous capacity burden the pandemic placed on hospitals and traditional care settings. Every day, we see that care is moving increasingly to surgery centers, ambulatory centers, retail clinics and into the home.

This shift is creating significant opportunities for us to deliver solutions that will improve patient outcomes in those settings. For example, we’re addressing blood collection and diagnostics at the point of care, non-acute medication management, self-administered drug delivery and the home incontinence market.

Chronic Disease Outcomes

While we’ve been committed to improving chronic disease outcomes for a long time, innovation has typically fallen to the pharmaceutical industry—as new medications have set new treatment paradigms for people living with costly, complex chronic conditions.

Looking beyond medications, it’s no secret that patients with chronic conditions visit their healthcare providers and are often hospitalized more frequently than the general patient population. We believe this sets us up to usher in a new era of technical innovation in medical devices and improve chronic disease outcomes. We’re doing that by developing new solutions for increasingly prevalent, chronic conditions like peripheral vascular disease and end-stage kidney disease—while innovating in the tissue regeneration and reconstruction space and molecular diagnostics.

In the future, BD will have a core of smart and connected devices, be a market leader in new care settings, and be known for its tremendous impact on improving outcomes in chronic disease. We look forward to continuing to share our progress in advancing the world of health™.